Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Operations: 2011-2024

Historic Cash from Operations for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $12.1 million.

  • Niagen Bioscience's Cash from Operations rose 5.64% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 412.77%. This contributed to the annual value of $12.1 million for FY2024, which is 70.14% up from last year.
  • Niagen Bioscience's Cash from Operations amounted to $12.1 million in FY2024, which was up 70.14% from $7.1 million recorded in FY2023.
  • Niagen Bioscience's Cash from Operations' 5-year high stood at $12.1 million during FY2024, with a 5-year trough of -$24.2 million in FY2021.
  • Its 3-year average for Cash from Operations is $1.4 million, with a median of $7.1 million in 2023.
  • In the last 5 years, Niagen Bioscience's Cash from Operations slumped by 127.95% in 2021 and then surged by 147.14% in 2023.
  • Yearly analysis of 5 years shows Niagen Bioscience's Cash from Operations stood at -$10.6 million in 2020, then slumped by 127.95% to -$24.2 million in 2021, then skyrocketed by 37.52% to -$15.1 million in 2022, then surged by 147.14% to $7.1 million in 2023, then skyrocketed by 70.14% to $12.1 million in 2024.